



Aatmaj Healthcare Limited

Regd Office: "Jupiter Hospital", Opp. ICAI Bhawan, Sun Pharma Ataladra Road, Vadodara – 390012, Gujarat, India,
Email: info@jupiterhospitalvadodara.com ; CIN: U85100GJ2014PLC079062,
Website: jupiterhospitalvadodara.com, Contact No : 0265 2681568

AHL/NSE/5/24

May 25, 2024

The Manager, Listing Department
National Stock Exchange of India Limited
Exchange Plaza, 5th Floor, Plot No. C/1,
G Block, Bandra-Kurla Complex, Bandra (E),
Mumbai - 400 051, Maharashtra, India.

Symbol: AATMAJ / ISIN: INE00B201016

Dear Sir/Madam,

Sub: Outcome of Board meeting held on today i.e. Saturday, May 25, 2024, in terms of Regulation 30(6) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Pursuant to the Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that the Board of Directors of the Company, at their Board Meeting held on today, i.e. Saturday, May 25, 2024, at the Registered Office of the Company situated at "Jupiter Hospital", Opp. ICAI Bhawan, Sun Pharma Ataladra Road, Vadodara – 390012, Gujarat, India and which was commenced at 05.30 pm and concluded at 06.15 pm have inter-alia considered and approved the following:

1. Considered, approved and taken on record the Standalone Audited Standalone Financial Statements of the Company for the half year and Year ended on March 31, 2024 along with Auditors' Report thereon;


The said Financial Statements / Results were reviewed and recommended by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held today.
2. The Board of Directors of the company have recommended a final dividend of Rs. 0.05/- (par value of equity share of Rs. 5/- each) per equity share for the Financial year ended on March 31, 2024,. The payment is subject to the approval of shareholders in the ensuing Annual General Meeting of the Company. Final Dividend, if approved by the Members, will be paid after the ensuing Annual General Meeting.
3. Considered and approved all other business as per agenda circulated.

Kindly take the above on record and oblige us.

Thanking you.

Yours faithfully,

For Aatmaj Healthcare Limited


Tushar K Suvagiya
Managing Director

DIN : 06802410



Encl : As Stated Above



Aatmaj Healthcare Limited

Regd Office: "Jupiter Hospital", Opp. ICAI Bhawan, Sun Pharma Ataladra Road, Vadodara – 390012, Gujarat, India,
Email: info@jupiterhospitalvadodara.com ; CIN: U85100GJ2014PLC079062,
Website: jupiterhospitalvadodara.com, Contact No : 0265 2681568

AHL/NSE/5/24

May 25, 2024

The Manager, Listing Department
National Stock Exchange of India Limited
Exchange Plaza, 5th Floor, Plot No. C/1,
G Block, Bandra-Kurla Complex, Bandra (E),
Mumbai - 400 051, Maharashtra, India.

Symbol: AATMAJ / ISIN: INE0OB201016

Dear Sir/Madam,

Sub: Submission of Standalone Audited Financial Results of the Company for the half year and Financial Year ended on March 31, 2024 along with Auditors' Report thereon.

Ref: Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

With reference to captioned subject and pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the Standalone Audited Financial Results of the Company for the half year and Financial Year ended on March 31, 2024, Auditors' Reports on the aforesaid Audited Financial Results.

Kindly take the above on record and oblige us.

Thanking you.

Yours faithfully,

For Aatmaj Healthcare Limited

Tushar K Suvagiya
Managing Director
DIN : 06802410



Encl : As Stated Above



Aatmaj Healthcare Limited

(Formerly known as Aatmaj Healthcare Private Limited)

Regd Office: "Jupiter Hospital", Opp. ICAI Bhawan, Sun Pharma Ataladra Road, Vadodara – 390012, Gujarat, India,

Email: info@jupiterhospitalvadodara.com; CIN: U85100GJ2014PLC079062,

Website: jupiterhospitalvadodara.com, Contact No : 0265 2681568

**Audited Standalone Financial Results
of Aatmaj Healthcare Limited
for the half year and year ended March 31, 2024
pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligation and
Disclosure Requirements) Regulations, 2015, as amended.**

Particulars	Six Months ended			Year ended	
	31.03.2024 Audited (Refer Note 3)	30.09.2023 Unaudited	31.03.2023 Audited (Refer Note 3)	For the year ended March 31, 2024 Audited	For the year ended March 31, 2023 Audited
Revenue from operations	717.17	856.64	1374.07	1573.81	2716.26
Other income	61.08	23.60	-	84.68	2.64
Total Revenue	778.25	880.24	1374.07	1658.49	2718.90
Expenses					
Cost of Materials Consumed	174.69	71.73	56.16	246.42	174.16
Purchases of Stock-in-Trade	-	-	-	-	-
Changes in Inventories of Finished Goods, work-in-progress and Stock-in-Trade	-	-	-	-	-
Employee Benefits Expense	241.52	115.33	212.90	356.85	465.71
Finance costs	66.23	58.68	64.85	124.91	89.51
Depreciation and Amortization Expense	42.78	38.06	34.36	80.84	68.77
Other Expenses	433.09	282.11	580.16	715.20	1093.39
Total Expenses	958.31	565.91	948.43	1524.22	1891.54
Profit Before Tax	-180.06	314.33	425.64	134.27	827.36
Tax expense:					
Current tax	(45.00)	77.00	115.76	32.00	219.21
Deferred tax	5.47	8.72	9.38	14.19	17.50
Profit/(loss) for the period	(140.53)	228.61	300.50	88.08	590.65
Earnings per equity share:					
Basic	(0.62)	1.01	1.85	0.39	3.64
Diluted	(0.62)	1.01	1.85	0.39	3.64

On Behalf of the Board,
For Aatmaj Healthcare Limited

Tushar K Suvagiya
Managing Director
DIN: 06802410



Date: 25/05/2024
Place: Vadodara



Notes attached to audited Standalone Financial Results for the Half Year and Year ended March 31, 2024

1. The above standalone financial results of the company ("the statement") have been reviewed by the Audit Committee and subsequently approved by the Board of Directors of the Company at its Meeting held on May 25, 2024 and have been subjected to audit by the statutory auditors of the company on which the auditors have expressed an unmodified Opinion.
2. The Standalone Financial results has been prepared in accordance with recognition and measurement principles laid down in the Accounting Standard 25 "Interim Financial Reporting" (As 25) as prescribed under section 133 of the companies act, 2013 ("the Act") read with the Companies (Accounting Standards) Rules, 2021, as amended from time to time and other accounting principal generally accepted in India. These financial results are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with other relevant rules and circulars issued thereunder.
3. The figures for the Half year ended March 31, 2024 are the balancing figures between audited figures in respect of year ended March 31, 2024 and reviewed year to date figures for the half year ended September 30, 2023. The figures for the Half year ended March 31, 2023 are the balancing figures between audited figures in respect of year ended March 31, 2023 and the unaudited year to date figures for the half year ended September 30, 2023 were not subject to limited review by us.
4. The company is engaged primarily in the business of Operating Multi Specialty Hospitals and all its operations are in India only. Accordingly, there is no separate reportable segment as per AS 17 on "Segment Reporting" in respect of Company.
5. The Company applied to National Stock Exchange of India Limited ("NSE") for in-principle approval for listing its equity shares on the Emerge Platform of the NSE. National Stock Exchange of India Limited has, vide its letter dated June 1, 2023 granted it's In Principle Approval to the Company. The Company had filed Prospectus to the Registrar of the Company, Ahmedabad on June 13, 2023. The Public Issue was opened on Monday, June 19, 2023 and closed on Wednesday, June 21, 2023. The Basis of Allotment was finalized by Company, Registrar to the issue and Merchant Banker in consultation with the NSE on June 26, 2023. The Company applied for listing of its total equity shares to NSE and it has granted its approval vide its letter dated June 28, 2023. The trading of equity shares of the Company commenced w.e.f. June 30, 2023 at Emerge Platform of National Stock Exchange of India Ltd. (NSE). The IPO related expenses have been debited to the share premium account and the IPO proceeds which are not utilised till the date of balance sheet has been kept in the form of FDR in the bank.





Aatmaj Healthcare Limited

(Formerly known as Aatmaj Healthcare Private Limited)

Regd Office: "Jupiter Hospital", Opp. ICAI Bhawan, Sun Pharma Ataladra Road, Vadodara – 390012, Gujarat, India,

Email: info@jupiterhospitalvadodara.com; CIN: U85100GJ2014PLC079062,

Website: jupiterhospitalvadodara.com, Contact No : 0265 2681568

(Rs. in Lacs)

Sr. No.	Objects as per Prospectus	Allocation as per Prospectus	Fund utilised up to March 31, 2024	Balance as on March 31, 2024
1	Repayment/Prepayment in full or part of existing secured debt of the company	900.00	900.00	-
2	Funding the working capital requirements of the company	600.00	600.00	-
3	Purchase of medical equipment for hospitals of our company and/or newly acquired or set up hospitals	913.11	-	913.11
4	Our inorganic growth initiatives through acquisitions and other strategic initiatives	620.00	620.00	-
5	General Corporate Expenses	496.89	496.89	-
6	Issue Expenses	310.00	310.00	-
	Total Rs. In Lacs	3840.00	2926.89	913.11

- Audited statements of Assets and liabilities and Statement of Cash Flow are attached as "Annexure A" and "Annexure B" respectively.
- For the Financial year ending on March 31, 2024, the Board of Directors of the company have recommended a final dividend of Rs. 0.05/- (par value of equity share of Rs. 5/- each) per equity share. This payment is subject to the approval of shareholders in the ensuing Annual General Meeting of the Company.
- Previous year's/period's figures have been regrouped/reclassified whenever necessary.

On Behalf of the Board,
For Aatmaj Healthcare Limited

Tushar K Suvagiya
Managing Director
DIN: 06802410



Date: 25/05/2024

Place: Vadodara





Aatmaj Healthcare Limited

(Formerly known as Aatmaj Healthcare Private Limited)

Regd Office: "Jupiter Hospital", Opp. ICAI Bhawan, Sun Pharma Ataladra Road, Vadodara – 390012, Gujarat, India,

Email: info@jupiterhospitalvadodara.com; CIN: U85100GJ2014PLC079062,


Website: jupiterhospitalvadodara.com, Contact No : 0265 2681568

Annexure A: Standalone Statement of Assets and Liabilities

(Rs. In Lakhs)

Particulars	As at March 31, 2024	As at March 31, 2023
EQUITY AND LIABILITIES		
Shareholders' Funds		
Share capital	1,130.00	810.00
Reserves and surplus	3,818.23	607.76
	4,948.23	1,417.76
Non-Current Liabilities		
Long-term borrowings	124.00	179.27
Deferred Tax Liabilities (Net)	81.36	67.17
Other Long-term liabilities	-	-
Long-term provisions	-	-
	205.36	246.44
Current Liabilities		
Short - Term Borrowings	423.87	990.55
Trade payables	132.01	211.95
Other Current Liabilities	6.17	8.98
Short - Term Provisions	52.77	225.02
	614.82	1,436.50
TOTAL	5,768.41	3,100.70
ASSETS		
Non-Current Assets		
Property, Plant and Equipment		
Tangible assets	1,251.72	1,113.30
Intangible assets	566.16	3.78
Capital work-in-progress	-	-
Intangible assets under development	-	-
	1,817.88	1,117.08
Non-current investments	-	-
Long-term loans and advances	-	-
Other non-current assets	-	-
	1,817.88	1,117.08
Current assets		
Inventories	64.10	40.05
Trade receivables	2,061.68	1,782.61
Cash and cash equivalents	1,080.92	31.68
Short-term loans and advances	688.28	108.51
Other current assets	55.55	20.77
	3,950.53	1,983.62
TOTAL	5,768.41	3,100.70

On Behalf of the Board,
For Aatmaj Healthcare Limited


Tushar K Suvagiya
Managing Director

DIN: 06802410



Date: 25/05/2024
Place: Vadodara



ANNEXURE B : STANDALONE CASH FLOW STATEMENT

Particular	In Rs. Lakhs	
	31/03/2024	31/03/2023
Cash Flows from Operating Activates		
Net Profit Before Tax and Extra Ordinary Items	134.27	827.36
Adjustment For		
Depreciation		
Foreign Exchange	80.84	68.77
Gain or loss of Sale of Fixed assets		
Gain or loss of Investment		
Finance Cost		
Dividend Income	124.91	89.51
Other adjustment of non cash Item		
Other adjustment to reconcile Profit		
Total Adjustment to Profit/Loss (A)	205.75	158.29
Adjustment For working Capital Change		
Adjustment for Increase/Decrease in Inventories	-24.05	0.45
Adjustment for Increase/Decrease in Trade Receivables	-279.07	-1273.00
Adjustment for Increase/Decrease in Other Current Assets	-614.55	-37.88
Adjustment for Increase/Decrease in Trade Payable	-79.94	48.18
Adjustment for Increase/Decrease in other current Liabilities	-2.81	544.06
Adjustment for Provisions	-172.25	46.20
Total Adjustment For Working Capital (B)	-1172.66	-671.99
Total Adjustment to reconcile profit (A+B)	-966.91	-513.70
Net Cash flow from (Used in) operation	-832.65	313.66
Dividend Received		
Interest received		
Interest Paid		
Income Tax Paid/ Refund	32.00	219.21
Net Cash flow from (Used in) operation before Extra-Ordinary Items	-800.65	532.87
Proceeds from Extra Ordinary Items		
Payment for Extra Ordinary Item		
Net Cash flow From operating Activities	-800.65	532.87
Cash Flows from Investing Activities		
Proceeds From fixed Assets		
Proceeds from Investment or Equity Instruments	0.00	-0.30
Purchase of Fixed Assets	781.64	98.40
Purchase Of Investments or Equity Instruments		
Interest received	0.00	0.00
Dividend Received		
Cash Receipt from Sale of Interest in Joint Venture		
Cash Payment to acquire Interest in Joint Venture	0.00	43.00
Cash flow from loosing Control of subsidiaries		
Cash Payment for acquiring Control of subsidiaries		
Proceeds from Govt. Grant		
Other Inflow/Outflow Of Cash	0.00	0.00




Aatmaj Healthcare Limited

(Formerly known as Aatmaj Healthcare Private Limited)

Regd Office: "Jupiter Hospital", Opp. ICAI Bhawan, Sun Pharma Ataladra Road, Vadodara – 390012, Gujarat, India,
Email: info@jupiterhospitalvadodara.com; CIN: U85100GJ2014PLC079062,
Website: jupiterhospitalvadodara.com, Contact No : 0265 2681568

Net Cash flow from (Used in) in Investing Activities before Extra Ordinary Items	-781.64	-141.70
Proceeds from Extra Ordinary Items		
Payment for Extra Ordinary Item		
Net Cash flow from (Used in) in Investing Activities	-781.64	-141.70
Cash Flows from Financial Activities		
Proceeds From Issuing Shares	3432.37	0.00
Proceeds from Issuing Debenture /Bonds/Notes		
Redemption of Preference Share		
Redemption of Debenture		
Proceeds from other Equity Instruments		
Proceeds From Borrowing	0.00	-32.59
Repayment Of Borrowing	675.94	344.96
Dividend Paid		
Interest Paid	124.91	0.00
Income Tax Paid/Refund		
Net Cash flow from (Used in) in Financial Activities before Extra Ordinary Items	2631.52	-377.55
Proceeds from Extra Ordinary Items		
Payment for Extra Ordinary Item		
Net Cash flow from (Used in) in Financial Activities	2631.52	-377.55
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes	1049.23	13.62
Effect of exchange rate change on cash and cash equivalents		
Net increase (decrease) in cash and cash equivalents	1049.23	13.62
Cash and cash equivalents at beginning of period	31.69	18.07
Cash and cash equivalents at end of period	1080.92	31.69

On Behalf of the Board,
For Aatmaj Healthcare Limited



Tushar K Suvagiya
Managing Director
DIN: 06802410



Date: 25/05/2024
Place: Vadodara



Independent Auditor's Report
On the Audited Standalone Financial Results
of Aatmaj Healthcare Limited
for the half year and year ended March 31, 2024
pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligation
and Disclosure Requirements) Regulations, 2015, as amended.

To,
The Board of Directors of
AATMAJ HEALTHCARE LIMITED
(Formerly Known as Aatmaj Healthcare Private Limited).
Vadodara

Opinion

We have audited the Financial Results for the half year and year ended March 31, 2024 ("Financial Results") included in the accompanying "Statement of Audited Financial Results for the Half year and Year ended 31st March, 2024 of **AATMAJ HEALTHCARE LIMITED** (Formerly Known As Aatmaj Healthcare Private Limited) ("the Company"), (Statement") being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, as amended ("the Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, the Standalone Financial Results for the Half year and Year ended March 31, 2024:

- (i) is presented in accordance with the requirements of Regulation 33 of the Listing Regulations; and
- (ii) give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at March 31, 2024, and its profit/loss, (*changes in equity*) and its cash flows for the year ended on that date.

Basis for Opinion

We conducted our audit of the Financial Statements in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013. Our responsibilities under those Standards are further described in the *Auditor's Responsibilities for the Audit of the Financial Statements for the half year and year ended March 31, 2024* section of our report. We are independent of the Company in accordance with the *Code of Ethics* issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the Financial Statements for the year ended March 31, 2024 under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Management's Responsibility for the Financial Statements

The Company's Board of Directors is responsible for the matters stated in section 134(5) of the Companies Act, 2013 ("the Act") with respect to the preparation of these Financial Statements that give a true and fair view of the financial position, financial performance, (changes in equity) and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the accounting Standards specified under section 133 of the Act and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Financial Statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the Financial Statements, the Board of Directors is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Those Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Financial Results for the year ended 31st March, 2024

Our objectives are to obtain reasonable assurance about whether the Standalone Financial Results for the half year and year ended 31st March, 2024 as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these Financial Statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- i) Identify and assess the risks of material misstatement of the Financial Statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- ii) Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion of the effectiveness of the Company's internal control.

- iii) Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- iv) Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Annual Standalone Financial Results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- v) Evaluate the overall presentation, structure and content of the Annual Standalone Financial Results, including the disclosures, and whether the Annual Standalone Financial Results represent the underlying transactions and events in a manner that achieves fair presentation.
- vii) Evaluate the appropriateness and reasonableness of disclosure made by the Board of Directors in terms of the requirements specified under Regulation 33 of the Listing Regulations.

Materiality is the magnitude of misstatements in the Annual Standalone Financial Results that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the Financial Statements may be influenced. We consider quantitative materiality and qualitative factors in

- (i) Planning the scope of our audit work and in evaluating the results of our work; and
- (ii) to evaluate the effect of any identified misstatements in the Financial Statements.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matter


Attention is drawn to the fact that:

- (i) The Statements includes the results for the half year ended March 31, 2024 being the balancing figure between the audited figures in respect of the full financial year ended March 31, 2024 and the reviewed year to date figures for the half year ended September 30, 2023.
- (ii) The Statement includes the results for the half year ended March 31, 2023 being the balancing figure between the audited figures in respect of the full financial year ended March 31, 2023 and the unaudited year to date figures for the half year ended September 30, 2022. Figures for the half year ended September 30, 2022 were not subject to limited review by us.

- (iii) Comparative figures for the year ended as at March 31, 2023 are as per financial statements prepared in connections with SME – IPO which was subject to our audit and we have expressed an unmodified opinion on the same vide our Audit Report dated August 29, 2023.

Our opinion on the statement is not modified in respect of these matters.

For Bela Mehta and Associates
Chartered Accountants
FRN: 101073W



Shital S Parikh
M.No.: 121609
UDIN: 24121609BKGXMF6616



Date: 25/05/2024
Place: Vadodara